Oladele Olusanya, MD
Family Medicine · Dallas, TXNPI 1073542429
Payments from drug & device makers
Across 91 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$304
- GSK$197
- Lilly USA, LLC$140
- Abbott$97
- Pfizer$90
- Amgen$85
- plus $673 from 24 others
What the payments were for
- Food & beverage$1,586100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $304 |
| GSK | 12 | $197 |
| Lilly USA, LLC | 8 | $140 |
| Abbott | 4 | $97 |
| Pfizer | 6 | $90 |
| Amgen | 4 | $85 |
| Exact Sciences | 3 | $64 |
| Hologic Sales And Service, LLC | 2 | $52 |
| AbbVie | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| AstraZeneca | 3 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Valeritas, Inc. | 1 | $28 |
| Alkermes, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Novartis | 1 | $16 |
| Smith+Nephew | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Echosens North America, Inc. | 1 | $10 |
How this compares
$1,586 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $51,157 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 65 | $48,593 |
| Advair HfaFluticasone Propion/Salmeterol | 106 | $39,717 |
| MounjaroTirzepatide | 23 | $26,231 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $22,918 |
| TradjentaLinagliptin | 33 | $22,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,762 |
| Levemir FlexpenInsulin Detemir | 52 | $13,011 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 298 | $12,924 |
| JanuviaSitagliptin Phosphate | 18 | $11,908 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $11,751 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $11,196 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $10,918 |
| Novolog FlexpenInsulin Aspart | 78 | $10,786 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $8,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $304 | $55,50067 claims |
| Lilly USA, LLCMounjaro | $140 | $26,23123 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $197 | $23,25435 claims |
| Boehringer IngelheimTradjenta | $21 | $22,58733 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $41 | $21,55033 claims |
| PfizerEliquis | $90 | $7,57113 claims |
| Sanofi-aventis U.S. LLCLantus | $33 | $2,25611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Dallas
- Thomas KingDallas$12M
- Jennifer ZonDallas$5.9M
- Chrisette DharmagunaratneDallas$5.6M
- Michele ReynoldsDallas$3.8M
- Shiwali RaiDallas$2.8M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.